Stylianos Korasidis

Dr. Stylianos Korasidis

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
MAMarcello Carlo Ambrogi
Marcello Carlo Ambrogi
PBPietro Bertoglio
Pietro Bertoglio
VAVittorio Aprile
Vittorio Aprile
ACAntonio Chella
Antonio Chella
SKStylianos Korasidis
Stylianos Korasidis
AMAlfredo Mussi
Alfredo Mussi

9 February 2015 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
PDF file
MAMarcello Carlo Ambrogi
Marcello Carlo Ambrogi
SKStylianos Korasidis
Stylianos Korasidis
MLMarco Lucchi
Marco Lucchi
OFOlivia Fanucchi
Olivia Fanucchi
SGSilvia Giarratana
Silvia Giarratana
AMAlfredo Mussi
Alfredo Mussi
OBJECTIVES Recurrences of thymoma are described in 10–30% of cases up to 10 years after surgical resection. Herein we report our experience with surgical removal of pleural recurrences followed by hyperthermic intrathoracic perfusion chemotherapy (HITHOC). METHODS We prospectively collected data of patients with pleural recurrence of thymoma who underwent surgery followed by HITHOC. After thoracotomy had been closed, drainages were connected to a dedicated perfusion machine, pleural space was filled with saline solution, progressively heated up to 42.5°C. At this time, chemotherapeutic agents (Doxorubicin and Cisplatin) were injected and perfusion lasted 60 min. RESULTS In the period 2005–2012, 13 consecutive patients have been treated (8 males, 5 females, mean age 46 years). Initial Masaoka-Koga stage was 2 IIa, 5 IIb, 5 III, 1 IVa. Disease-free interval was 47.2 months on average [standard deviation (SD): 25.5]. Nine patients presented paraneoplastic syndromes (8 myasthenia gravis and 1 red cell aplasia). Complete resection was achieved in all cases except one. HITHOC was successfully performed in all cases and no signs or symptoms of toxicity were recorded in the perioperative period. With a mean follow-up period of 64.6 months (SD: 32.5), 1 patient died for toxicity following systemic chemotherapy, another one died disease-free, 4 patients developed pleural relapses (2 ipsilateral, 2 contralateral) and 1 mediastinal and abdominal nodal metastases. Mean survival was 58 months [SD: 34.4), median survival by the Kaplan–Meier method was not reached while 5-year actuarial survival was 92%. CONCLUSIONS HITHOC was shown to be feasible and safe. In terms of efficacy, it seems promising but multicentre studies and a longer follow-up period are required to ascertain its effectiveness.

14 March 2020 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Closed access
VAVittorio Aprile
Vittorio Aprile
DBDiana Bacchin
Diana Bacchin
SKStylianos Korasidis
Stylianos Korasidis
ANAgnese Nesti
Agnese Nesti
EMElena Marrama
Elena Marrama
MLMarco Lucchi
Marco Lucchi
OBJECTIVES: Recurrence of thymoma is described in 10–30% of cases after surgical resection. Iterative surgery for thymoma pleural relapses (TPRs) is often part of a multimodal treatment. Hyperthermic intrathoracic chemotherapy (HITHOC) following macroscopic radical surgery is an option that combines the effects of mild hyperthermia with those of chemotherapeutic agents. We evaluated the effectiveness of surgery + HITHOC, compared with surgery alone, in the treatment of TPR. METHODS: We retrospectively collected data of all patients who underwent surgery for TPR in our centre from 2005 to 2017. Relapses were treated by partial pleurectomy with radical intent, followed by HITHOC when not contraindicated. Patients were divided into 2 groups: surgery + HITHOC and surgery alone. We collected demographic and clinical data and analysed postoperative results together with oncological outcomes. RESULTS: Forty patients (27: surgery + HITHOC, 13: surgery alone), mean age 49.8 (±13.7) years, were included in this study. There were no perioperative deaths. We experienced 33.3% perioperative morbidity in the surgery + HITHOC group compared with 23.1% in the surgery alone group (P = 0.71). The overall survival rate was comparable between the 2 groups (P = 0.139), whereas the local disease-free interval was 88.0 ± 15 months in the surgery + HITHOC group and 57 ± 19.5 months in the surgery alone group (P = 0.046). The analysis of factors affecting the outcomes revealed that radical surgery is related with a better survival rate whereas the local disease-free interval was significantly influenced by HITHOC. CONCLUSIONS: The safety and feasibility of HITHOC in the treatment of TPR are already known, even if it should be reserved for selected patients. Surgery + HITHOC seems to be associated with a longer local disease-free time compared to surgery alone.

1 June 2010 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
SKStylianos Korasidis
Stylianos Korasidis
CAClaudio Andreetti
Claudio Andreetti
ADAntonio D'ANdrilli
Antonio D'ANdrilli
MIMohsen Ibrahim
Mohsen Ibrahim
ACAnnamaria Ciccone
Annamaria Ciccone
ERErino A. Rendina
Erino A. Rendina
Postoperative air leaks associated with residual pleural space is a well known complication contributing to prolong hospitalization. Many techniques

1 July 2014 in Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery
Verified
Journal Article
Closed access
MAMarcello C. Ambrogi
Marcello C. Ambrogi
OFOlivia Fanucchi
Olivia Fanucchi
SKStylianos Korasidis
Stylianos Korasidis
FDFederico Davini
Federico Davini
RGRaffaello Gemignani
Raffaello Gemignani
AMAlfredo Mussi
Alfredo Mussi
Objective: During the past 20 years, the use of video-assisted thoracoscopic surgery has increased as an important minimally invasive tool. To further reduce its invasiveness, after a preliminary experience, we decided to use a nonintubated spontaneous breathing general anesthesia, for video-assisted thoracoscopic surgery resection of lung nodule, using a laryngeal mask (LMA). This study aimed to verify the safety and the feasibility of this technique. Methods: Twenty consecutive patients who underwent thoracoscopic wedge of lung nodule under spontaneous breathing general anesthesia with LMA are the subjects of this study. Clinical data, American Society of Anesthesiologists status, Adult Comorbidity Evaluation-27 score, and Revised Cardiac Risk Index score were recorded for each patient. General inhalatory anesthesia (sevoflurane) was given in all cases through an LMA, without muscle relaxants, thus allowing spontaneous breathing. All procedures were performed in the lateral decubitus position. The maximum and minimum values of end-tidal carbon dioxide tension and oxygen saturation were recorded during the procedure. The level of technical feasibility was stratified by the operating surgeon according to four levels: excellent, good, satisfactory, and unsatisfactory. Results: There were 13 men and 7 women (mean age, 57 years). The mean induction anesthesia time was 6 minutes, whereas the mean operative time was 38 minutes. The values of oxygen saturation as well as minimum and maximum end-tidal carbon dioxide tension were 99.1%, 33.6 mm Hg, and 39.1 mm Hg, respectively. No mask displacement occurred. The mean operative time was 38 minutes (range, 25–90 minutes). The level of technical feasibility was defined as excellent in 19 cases and good in 1 case. No mortality occurred. Morbidity consisted of pleural effusion (one case), which was medically resolved. The mean postoperative stay was 3.5 days. Histopathologic results were one squamous cell lung cancer (lung primary), one adenocarcinoma (lung primary), five metastasis from colon cancer, four metastasis from breast cancer, three metastasis from renal cancer, three sarcoidosis, two amartocondroma, and one tuberculosis. Conclusions: Our experience suggests that thoracoscopic wedge resection of lung nodule is safe and feasible under spontaneous breathing anesthesia with LMA. This technique permits a confident manipulation of lung parenchyma and a safe stapler positioning, without cough, pain, or panic attack described for awake epidural anesthesia, avoiding the risks related to tracheal intubation and mechanical ventilation.

25 August 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VAVittorio Aprile
Vittorio Aprile
ALAlessandra Lenzini
Alessandra Lenzini
Filippo LococoFilippo Lococo
Filippo Lococo
DBDiana Bacchin
Diana Bacchin
SKStylianos Korasidis
Stylianos Korasidis
MLMarco Lucchi
Marco Lucchi
Introduction: Malignant Pleural Mesothelioma (MPM) is characterized by an aggressive behavior and an inevitably fatal prognosis, whose treatment is still far from being standardized. The role of surgery is questionable since a radical resection is unattainable in most cases. Hyperthermic IntraTHOracic Chemotherapy (HITHOC) combines the advantages of antitumoral effects together with those of high temperature on the exposed tissues with the aim to improve surgical radicality. Material and Methods: this is a narrative review on the role of HITHOC in the management of MPM patients. To provide data on the beginnings and the historical evolution of this technique, we searched the available literature by selecting the more exhaustive papers on this topic. Results: from 1994 to date different authors experimented HITHOC following a cytoreductive surgery in MPM, obtaining in most cases a good local control and a better overall survival associated to very low complication rate. Conclusions: HITHOC may be considered as a safe, feasible and effective procedure although there is a high heterogeneity between different protocols adopted worldwide. More structured studies are needed to reach a unanimous consensus on this technique.